Table 1.
Clinical and imaging characteristics
| Clinical and imaging biomarkers | N (%) | Biomarkers for prediction | ||
|---|---|---|---|---|
| PCT IGR | NCT IGR | mRS | ||
| Clinical characteristics Total number of patients | 232 | |||
| Age in years (median [IQR]) | 69.5 [58.8, 78.0] | + | + | + |
| Female (%) | 111 (47.8) | + | + | + |
| Hypertension (%) | 137 (59.1) | + | + | + |
| Diabetes mellitus (%) | 44 (19.0) | + | + | + |
| Glucose (mg/dl) (median [IQR]) | 6.7 [5.9, 7.8] | + | + | + |
| Hyperlipidemia (%) | 160 (69.0) | + | + | + |
| Statin use (%) | 57 (24.6) | + | + | + |
| Atrial fibrillation (%) | 102 (44.0) | + | + | + |
| NIHSS | 17 (12.21) | + | + | + |
| Cardiovascular (%) | 26 (11.2) | + | + | + |
| Smoking status (%) | + | + | + | |
| Never smoked | 139 (59.9) | |||
| Active smoker or stopped < 2 years ago | 62 (26.7) | |||
| Stopped smoking > 2 years ago | 31 (13.4) | |||
| Imaging biomarkers Time since symptom onset (h) (median [IQR]) | 2.5 [1.8, 4.5] | |||
| ASPECT score (median [IQR]) | 7.0 [5.0, 8.0] | + | ||
| NCT infarct volume (ml) (median [IQR]) | 32.2 [11.5, 59.8] | + | ||
| PCT infarct volume (ml) (median [IQR]) | 58.3 [25.0, 110.0] | + | ||
| Penumbra volume(ml) (median [IQR]) | 119.85 [78.67, 160.2] | + | + | + |
| Occlusion site (%) | + | + | + | |
| ICA and M1 and M2 | 55 (23.7) | |||
| ICA and M1 | 25 (10.8) | |||
| M1 and M2 | 104 (44.8) | |||
| M1 only | 48 (20.7) | |||
| Collateral (%) | + | + | ||
| Absent collaterals | 26 (11.2) | |||
| Collaterals filling < 50% of occluded territory | 102 (44.0) | |||
| 50% ≤ collaterals filling < 100% occluded territory | 72 (31.0) | |||
| Collaterals filling 100% of occluded territory | 32 (13.8) | |||
| Recanalization (%) | 146 (62.9) | + | ||
ASPECT: Alberta Stroke Program Early CT; ICA: Internal Carotid Artery; IGR: infarct growth rate; IQR: interquartile range; mRS: modified Rankin Scale; NCT: noncontrast head CT; NIHSS: National Institutes of Health Stroke Scale; PCT: perfusion CT.